A method of treatment of diarrhea-predominant IBS in a subject, comprising administering a composition comprising cilansetron or a pharmaceutically acceptable derivative thereof to achieve a plasma cilansetron concentration between about 0.1 ng/mL and about 25 ng/mL.
展开▼